Talis Biomedical Corporation Share Price

Equities

TLIS

US87424L2079

Biotechnology & Medical Research

Market Closed - Nasdaq 21:30:00 26/04/2024 BST 5-day change 1st Jan Change
9.14 USD +1.56% Intraday chart for Talis Biomedical Corporation +2.70% +22.68%
Sales 2022 4.81M 385M Sales 2023 2.13M 171M Capitalization 13.57M 1.09B
Net income 2022 -113M -9.05B Net income 2023 -62M -4.96B EV / Sales 2022 -17.6 x
Net cash position 2022 96.61M 7.73B Net cash position 2023 57.06M 4.57B EV / Sales 2023 -20.4 x
P/E ratio 2022
-0.11 x
P/E ratio 2023
-0.22 x
Employees 99
Yield 2022 *
-
Yield 2023
-
Free-Float 91.69%
More Fundamentals * Assessed data
Dynamic Chart
North American Morning Briefing : Stocks Seen -2- DJ
Talis Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : Stock Futures Muted; Nvidia Slips in Offhours Trading DJ
Talis Biomedical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Talis Biomedical Announces Exploration of Strategic Alternatives CI
Talis Biomedical Corporation Announces Resignation of Melissa Gilliam from its Board of Directors, as Member of Nominating and Corporate Governance Committee and as Member and Co-Chairperson of Science, Technology and Clinical Affairs Committee CI
BTIG Adjusts Talis Biomedical's Price Target to $5 From $5.25, Keeps Sell Rating MT
Talis Biomedical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Transcript : Talis Biomedical Corporation, Q2 2023 Earnings Call, Aug 10, 2023
Talis Biomedical Corporation Announces Resignation of Andrew A. Lukowiak as President and Chief Scientific Officer CI
Talis Biomedical Corporation Announces New Data Supporting the Development of Its Planned CT/NG/TV and Vinal Infections Panels CI
Talis Biomedical Appoints Former Roche Molecular CEO Heiner Dreismann to Board of Directors CI
Talis Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Transcript : Talis Biomedical Corporation, Q1 2023 Earnings Call, May 11, 2023
Talis Biomedical Corporation Appoints Kimberly Popovits as Lead Independent Director CI
More news

Latest transcript on Talis Biomedical Corporation

1 day+1.56%
1 week+2.70%
Current month+4.46%
1 month+1.56%
3 months+16.14%
6 months+97.46%
Current year+22.68%
More quotes
1 week
8.60
Extreme 8.6001
9.20
1 month
7.50
Extreme 7.5001
9.20
Current year
7.01
Extreme 7.01
9.32
1 year
4.35
Extreme 4.35
9.32
3 years
4.35
Extreme 4.35
193.20
5 years
4.35
Extreme 4.35
508.50
10 years
4.35
Extreme 4.35
508.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 31/08/20
Director of Finance/CFO 51 31/12/21
Director/Board Member 65 30/07/20
Members of the board TitleAgeSince
Director/Board Member 56 29/02/16
Director/Board Member 66 31/12/13
Director/Board Member 65 30/07/20
More insiders
Date Price Change Volume
26/04/24 9.14 +1.56% 4,549
25/04/24 9 -2.18% 3,730
24/04/24 9.2 +2.11% 3,352
23/04/24 9.01 +0.11% 8,738
22/04/24 9 +1.12% 9,727

Delayed Quote Nasdaq, April 26, 2024 at 09:30 pm

More quotes
Talis Biomedical Corporation is engaged in transforming diagnostic testing by developing and commercializing products that are designed to enable molecular testing for infectious diseases and other conditions at the point of care. The Company is engaged in developing the Talis One system, a cloud-enabled molecular diagnostic platform. The Talis One system consists of compact instrument, single-use test cartridges and software that is designed to support a central cloud database, which work together and are designed to provide central laboratory levels of accuracy and be operated by an untrained user. It is also focused on developing Talis One assay kits for respiratory infections, and infections related to women's health and sexually transmitted infections (STIs). It is also developing influenza A and influenza B tests to be included as part of a respiratory panel with its COVID-19 assay (Respiratory Panel), as well as exploring adding a respiratory syncytial virus (RSV) test.
More about the company